| Entry |
|
|---|
| Name |
Alfuzosin (INN);
Xatral (TN) |
|---|
| Formula |
C19H27N5O4
|
|---|
| Exact mass |
389.2063
|
|---|
| Mol weight |
389.4488
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Cardiovascular agent
DG01466 Adrenergic receptor antagonist
DG01465 alpha-Adrenergic receptor antagonist
DG01457 alpha1-Adrenergic receptor antagonist
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
|
|---|
| Remark |
| Product (DG00489): | D01692<US> |
|
|---|
| Efficacy |
Antidysuria, Antihypertensive, alpha1-Adrenergic receptor antagonist |
|---|
| Comment |
Prazosin derivative
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
| hsa04270 | Vascular smooth muscle contraction |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576]
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
G GENITO URINARY SYSTEM AND SEX HORMONES
G04 UROLOGICALS
G04C DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY
G04CA Alpha-adrenoreceptor antagonists
G04CA01 Alfuzosin
D07124 Alfuzosin (INN)
Drug groups [BR:br08330]
Cardiovascular agent
DG01466 Adrenergic receptor antagonist
DG01465 alpha-Adrenergic receptor antagonist
DG01457 alpha1-Adrenergic receptor antagonist
DG00489 Alfuzosin
D07124 Alfuzosin
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00489 Alfuzosin
D07124 Alfuzosin
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Adrenaline
ADRA1A
D07124 Alfuzosin (INN)
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D07124
Drug groups [BR:br08330]
Cardiovascular agent
DG01466 Adrenergic receptor antagonist
DG01465 alpha-Adrenergic receptor antagonist
DG01457 alpha1-Adrenergic receptor antagonist
DG00489 Alfuzosin
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG00489 Alfuzosin
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 28
1 N5x N 26.1100 -9.5200
2 C8y C 26.1100 -8.1200
3 N5x N 27.3000 -7.4200
4 C8y C 28.4900 -8.1200
5 C8y C 28.4900 -9.5200
6 C8y C 27.3000 -10.2200
7 C8x C 29.7500 -7.4200
8 C8y C 30.9400 -8.1200
9 C8y C 30.9400 -9.5200
10 C8x C 29.7500 -10.2200
11 O2a O 32.1300 -10.2200
12 C1a C 33.3200 -9.5200
13 O2a O 32.1300 -7.4200
14 C1a C 33.3200 -8.0500
15 N1c N 24.8500 -7.4200
16 C1b C 23.6600 -8.0500
17 C1a C 24.8500 -5.9500
18 C1b C 22.4700 -7.4200
19 C1b C 21.2800 -8.0500
20 N1b N 20.0900 -7.4200
21 C5a C 18.9000 -8.0500
22 O5a O 18.9000 -9.5200
23 N1a N 27.3000 -11.6200
24 C1x C 15.4000 -7.2800
25 C1x C 15.8900 -5.9500
26 C1x C 17.2900 -5.9500
27 C1y C 17.7100 -7.3500
28 O2x O 16.5200 -8.1200
BOND 30
1 1 2 1
2 2 3 2
3 3 4 1
4 4 5 2
5 5 6 1
6 1 6 2
7 4 7 1
8 7 8 2
9 8 9 1
10 9 10 2
11 5 10 1
12 9 11 1
13 11 12 1
14 8 13 1
15 13 14 1
16 2 15 1
17 15 16 1
18 15 17 1
19 16 18 1
20 18 19 1
21 19 20 1
22 20 21 1
23 21 22 2
24 6 23 1
25 24 25 1
26 25 26 1
27 26 27 1
28 27 28 1
29 24 28 1
30 21 27 1
|
|---|
